SurgiLight secures funding
This article was originally published in The Gray Sheet
Executive Summary
Ophthalmic laser firm seals $500,000 private placement with accredited investor group Jan. 24. The firm will use the proceeds to expand a U.S. trial of its OptiVision presbyopia system and repay a credit line requested by Merrill Lynch in a Jan. 6 lawsuit (1"The Gray Sheet" Jan. 13, 2003, p. 19)...
You may also be interested in...
Expanded OptiVision Presbyopia Reversal Trial On SurgiLight’s Horizon
SurgiLight will need additional funding to support expansion of its IDE trial for the OptiVision presbyopia reversal system, following a lawsuit filed by Merrill Lynch over its credit line
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.